Abstract
FOXO3 is a tumor suppressor that orchestrates the expression of genes that regulate cell cycle progression, apoptosis, metabolism, oxidative stress, and other important cellular processes. Its inactivation is closely associated with tumorigenesis and cancer progression. On the other hand, sirtuin proteins have been demonstrated to be able to deacetylate, thus causing FOXO3 inactivation at the posttranslational level. Therefore, targeting sirtuin proteins renders new avenues for breast cancer treatment. Here, we describe three procedures for studying FOXO3 posttranslational modifications controlled by sirtuin proteins in cancer cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Myatt SS, Lam EWF (2007) The emerging roles of forkhead box (fox) proteins in cancer. Nat Rev Cancer 7(11):847–859
Schmidt M, de Mattos SF, van der Horst A, Klompmaker R, Kops GJPL, Lam EWF, Burgering BMT, Medema RH (2002) Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22(22):7842–7852
Medema RH, Kops GJPL, Bos JL, Burgering BMT (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27(kip1). Nature 404(6779):782–787
Zhao F, Lam EW (2012) Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med 6(4):376–380
Daitoku H, Sakamaki J, Fukamizu A (2011) Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 1813(11):1954–1960
McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JMM, Polychronis A, Coombes RC, Lam EWF (2009) Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 8(3):582–591
Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EWF (2010) SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9(4):844–855
Alcain FJ, Villalba JM (2009) Sirtuin inhibitors. Expert Opin Ther Pat 19(3):283–294
Lam EW, Brosens JJ, Gomes AR, Koo CY (2013) Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer 13(7):482–495
Shiota M, Yokomizo A, Kashiwagi E, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Seki N, Naito S (2010) Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101(5):1177–1185
Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, Deng SC, Liu Y, Liu L, Wang B, Tian K, Wang GB, Wang CY (2011) SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 18(9):920–928
Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL (2001) Identification of a class of small molecule inhibitors of the Sirtuin family of NAD-dependent Deacetylases by phenotypic screening. J Biol Chem 276(42):38837–38843
Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837):516–519
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Yao, S., Mahmud, Z., Sachini, N., Aimjongjun, S., Saavedra-GarcĂa, P., Lam, E.WF. (2019). Characterization of FOXO Acetylation. In: Link, W. (eds) FOXO Transcription Factors. Methods in Molecular Biology, vol 1890. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-8900-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8900-3_7
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-8899-0
Online ISBN: 978-1-4939-8900-3
eBook Packages: Springer Protocols